Click Here – Founder’s Vision Immunotherapy 2.0
Click Here – 2025 Investor Key Opinion Leader Conference
For inquiries regarding Dr. Patrick Soon-Shiong’s recent interview on BioShield, please send us an email
Global Chief Scientific and Medical Officer, ImmunityBio
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both the innate and adaptive branches of the immune system, to facilitate the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
Smart Therapies for Difficult Diseases®
Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle offense” designed to deliver durable, complete responses in cancer and infectious diseases.
Investigational Cancer Therapies and Vaccines
ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ natural killer (NK) cells, T cells, and macrophages, and establishment of immune memory by dendritic cells. We believe this comprehensive immunotherapy approach holds greater potential than CAR-T therapies or checkpoint inhibitors alone. We are also leveraging our established neoepitope prediction pipeline to predict which unique tumor-associated neoepitope peptides have the potential to trigger an effective, anti-tumor immune response when delivered to patients as a personalized vaccine. Clinical trials to assess the safety and efficacy of orchestrated use of these unique, complementary therapies and vaccine candidates are in progress across multiple tumor types.
Investigational Viral Therapies
Our recent findings from studies in HIV-infected patients show that cells infected with HIV can be exposed by our immune enhancer ANKTIVA to enable recognition and killing. This approach offers an opportunity for HIV patients to achieve a cure, and freedom from life-long anti-viral therapy. Tying viral infection and cancer together, we are developing a human papilloma virus (HPV) vaccine that has the potential to not only eradicate infection, but reduce the risk for HPV-associated cancers such as head/neck and cervical cancer.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
A Robust Clinical Pipeline
We are applying our science and platforms, including the development of potential cancer vaccines, to treat cancers, as well as developing immuno- and cell therapies that we believe could sharply reduce or eliminate the need for standard high-dose chemotherapy.
Latest News & Events
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
CIS with or without Papillary: Oral presentation from QUILT-3.032 study showed 71% complete response rate (N=100),...
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in...
ASCO 2025 Annual Meeting
ASCO Annual Meeting 2025 Date: May 29 - Jun 03, 2025 Location: Chicago, IL